Faecalibacterium Prausnitzii

The most abundant bacterium in the healthy human colon (5-15% of total fecal microbiota), F. prausnitzii is the premier butyrate producer in the gut and a cornerstone of anti-inflammatory intestinal homeostasis. Its depletion is one of the most consistent microbiome signatures across diseases linked to metal dyshomeostasis, and it has been directly demonstrated to protect against arsenic toxicity.

Butyrate Production and Barrier Protection

  • Produces butyrate as its primary fermentation end-product. Butyrate is the preferred energy source for colonocytes and the most potent SCFA for:
  • Strengthening tight junction protein expression (ZO-1, occludin, claudin-1).
  • Suppressing NF-kB-mediated inflammation via HDAC inhibition and GPR109A signaling.
  • Promoting regulatory T cell (Treg) differentiation — critical for immune tolerance.
  • Maintaining epithelial oxygen consumption, preserving the anaerobic luminal environment that favors beneficial obligate anaerobes over facultative pathobionts.
  • Butyrate production depends on iron-sulfur cluster enzymes in the butyrate synthesis pathway, connecting this commensal's function indirectly to iron availability.

Protection Against Metal Toxicity

Arsenic

  • The landmark Coryell et al. (2018) study demonstrated that F. prausnitzii is sufficient for at least partial protection against acute arsenic toxicity [1].
  • Germ-free mice mono-associated with E. coli alone died rapidly from arsenic exposure; bi-colonization with E. coli + F. prausnitzii significantly extended survival.
  • F. prausnitzii abundance was consistently associated with survival across human stool transplant experiments.
  • The gut microbiome is required for full arsenic protection; antibiotic-treated mice accumulate more arsenic in organs and excrete less in feces.

Cadmium and Lead

  • Depleted by cadmium and lead exposure in multiple mouse models [2].
  • Its loss under Cd/Pb exposure reduces butyrate production, compromising barrier integrity and increasing systemic metal absorption — a vicious cycle.
  • Classified as a next-generation probiotic for metal detoxification alongside akkermansia muciniphila [2].

Mechanism

  • Protective mechanisms likely include: maintenance of anaerobic barrier conditions, butyrate-mediated tight junction support, anti-inflammatory signaling that limits metal-induced epithelial damage, and possible arsenic biotransformation by associated microbiome members.

Depletion Across Disease States

F. prausnitzii depletion is among the most reproducible microbiome findings in disease:

  • IBD (Crohn's disease): dramatically reduced; inversely correlated with disease severity and relapse risk. The strongest single-organism biomarker for Crohn's remission.
  • Multiple sclerosis: decreased in MS patients; negatively associated with TNF-alpha levels [3] [4] [5].
  • Parkinson's disease: reduced abundance linked to decreased butyrate and increased gut permeability, potentially facilitating alpha-synuclein propagation via the gut brain axis [6] [7] [8].
  • Chronic kidney disease: depleted, contributing to uremic toxin accumulation; butyrate-producing taxa are reduced with disease progression [9] [10].
  • Type 2 diabetes: inversely correlated with HbA1c and fasting glucose; fiber interventions that restore F. prausnitzii improve glycemic control [11] [12].
  • Autism spectrum disorder: reduced; butyrate-producer depletion is a recurring ASD signature and Faecalibacterium hominis-derived indole signaling via AhR is under active study [13] [14].
  • Schizophrenia: altered SCFA producers including F. prausnitzii are linked to ultra-high-risk state and symptom severity [15] [16].
  • Graves' disease: negatively correlated with FT3, FT4, and TRAb but positively correlated with TSH; berberine supplementation increased F. prausnitzii alongside thyroid function recovery [17].
  • Obesity: inversely correlated with BMI and metabolic inflammation [18].
  • Colorectal cancer: reduced; butyrate loss may diminish anti-tumorigenic HDAC inhibition [19] [20].
  • Post-COVID / Long COVID: depletion of SCFA producers including F. prausnitzii associated with altered immune response [21].

The Metal-Dysbiosis-Disease Cycle

F. prausnitzii sits at the center of a recurring pattern across this wiki's disease pages: environmental metal exposure (As, Cd, Pb, Ni) depletes F. prausnitzii and other SCFA producers, reducing butyrate, compromising barrier integrity, increasing systemic metal absorption, and driving the chronic inflammation that underlies diverse diseases. Restoring F. prausnitzii through probiotic supplementation or dietary intervention is a logical intervention point in this cycle.

Key Sources

Connections

  • gut metal microbiome — central commensal in the metal-microbiome bidirectional axis
  • akkermansia muciniphila — metabolic cross-feeding partner; co-depleted in disease
  • arsenic — directly protective against arsenic toxicity (Coryell 2018)
  • cadmium — depleted by Cd exposure; loss amplifies toxicity
  • lead — depleted by Pb exposure
  • iron — Fe-S cluster enzymes in butyrate pathway; iron perturbation may affect function
  • inflammation — anti-inflammatory via butyrate/HDAC/GPR109A axis
  • dysbiosis — its depletion is the most consistent dysbiosis marker
  • lactobacillus — complementary SCFA producer; co-depleted under metal stress
  • gut brain axis — butyrate loss linked to neuroinflammation in PD and MS

References (23)

  1. . coryell 2018 gut microbiome arsenic toxicity protection
  2. . duan 2020 gut microbiota heavy metal probiotic strategy
  3. . bronzini 2023 feeding gut microbiome ms
  4. . olsson 2021 serum scfas inflammation newly diagnosed ms
  5. . becker 2021 scfas intestinal inflammation ms female susceptibility
  6. . pendergrass 2026 microbial metallomics parkinsons ferroptosis
  7. . aho 2021 gut microbiome scfas inflammation parkinsons
  8. . tan 2022 gut microbiome scfas parkinsons review
  9. . gao 2021 butyrate producing microbiota reduced ckd
  10. . he 2024 gut microbial scfas ckd
  11. . salamone 2021 gut microbiota scfa t2d dietary fibre
  12. . scfa 2020 dietary fiber t2d gut microbiome
  13. . yu 2025 faecalibacterium hominis indole ahr asd btbr
  14. . liu 2019 gut microbiota scfas asd chinese children
  15. . peng 2022 scfas schizophrenia ultra high risk
  16. . yu 2024 plasma cytokines scfas depression schizophrenia
  17. . han 2022 berberine methimazole graves microbiome
  18. . pendergrass 2026 heavy metals obesity epidemic
  19. . feitelson 2023 scfas cancer pathogenesis
  20. . carretta 2021 scfas receptors gut inflammation colon cancer
  21. . didenko 2025 intestinal microbiota scfa post covid immune response
  22. . ghosh 2023 heavy metals gut barrier integrity
  23. . zhu 2024 toxic essential metals gut microbiota